Corcept Therapeutics INC Form 4 insider transactions

Corcept Therapeutics Director Kimberly Park acquired 12,500 stock options with an exercise price of $59.69, vesting over one year.

Chief Business Officer Gary Charles Robb reported a series of stock gifts and trust transfers involving Corcept Therapeutics common stock.

Corcept Therapeutics Director James N. Wilson reported a gift of 2,000 shares of common stock.

Corcept Therapeutics Chief Development Officer William Guyer executed a series of transactions involving company stock, including the acquisition of stock options and the sale of common stock.

Corcept Therapeutics Director James N. Wilson reported the acquisition of 5,000 shares of common stock on April 6, 2026.

Corcept Therapeutics CEO Joseph K. Belanoff sold 26,198 shares of common stock for approximately $1.31 million under a pre-arranged 10b5-1 trading plan.

Corcept Therapeutics Director James N. Wilson reported gifting 4,000 shares of common stock as part of a routine transaction.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Corcept Therapeutics Director and 10% Owner G. Leonard Baker Jr. acquired 100,000 shares of common stock for approximately $3.3 million through pre-planned transactions.

Corcept Therapeutics Director James N. Wilson reported a planned gift of 28,000 common shares effective March 13, 2026, executed under a Rule 10b5-1 trading plan.

Corcept Therapeutics Director David L. Mahoney exercised stock options and subsequently transferred shares to a family trust, with some shares withheld for tax obligations.

Corcept Therapeutics' Chief Accounting & Technology Officer, Joseph Douglas Lyon, increased his direct beneficial ownership of common stock through a purchase plan and restricted stock awards, while also having shares withheld for tax obligations.

Corcept Therapeutics' President of Endocrinology, Sean Maduck, reported recent acquisitions of common stock through a purchase plan and restricted stock awards, alongside a tax-related disposition.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported the acquisition of 499 common shares and 499 unvested restricted stock awards, alongside a tax-related share withholding.

Corcept Therapeutics' Chief Development Officer, William Guyer, increased his direct ownership through a share purchase and restricted stock awards.

Corcept Therapeutics CFO Atabak Mokari increased his direct beneficial ownership through a purchase plan and restricted stock awards, while also disposing of shares for tax obligations.

Joseph Douglas Lyon, Corcept Therapeutics' Chief Accounting & Technology Officer, was granted 140,000 stock options with an exercise price of $35.70.

Corcept Therapeutics CEO Joseph K. Belanoff was granted 460,000 stock options with a $35.7 exercise price, vesting over four years.

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, was granted 140,000 stock options with an exercise price of $35.70.

Corcept Therapeutics granted its President of Endocrinology, Sean Maduck, 140,000 stock options with a $35.7 exercise price, vesting over four years.

Corcept Therapeutics' Chief Scientific Officer, Hazel Hunt, was granted 140,000 stock options with an exercise price of $35.70, vesting over four years.

Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, was granted 140,000 stock options with an exercise price of $35.70, vesting over four years.

Corcept Therapeutics' Chief Development Officer, William Guyer, was granted 140,000 stock options with an exercise price of $35.7 per share, vesting over four years.

Corcept Therapeutics director James N. Wilson exercised stock options and transferred a significant block of shares to a family trust.

Sean Maduck, President of Corcept Endocrinology, reported several non-cash transactions involving common stock, primarily transfers between trusts and LLCs.

Corcept Therapeutics' Chief Scientific Officer, Hazel Hunt, exercised stock options and subsequently sold shares to cover the exercise cost and tax obligations.

Corcept Therapeutics' Chief Development Officer, William Guyer, exercised stock options and subsequently sold 20,000 shares of common stock.

Corcept Therapeutics Director G. Leonard Baker Jr. exercised 140,000 stock options, increasing his indirect beneficial ownership.

William Guyer, Corcept Therapeutics' Chief Development Officer, executed a pre-planned transaction, exercising stock options and subsequently selling 20,000 common shares.

Corcept Therapeutics Director G. Leonard Baker Jr. reported a gift of limited partnership interests affecting his indirect beneficial ownership of company common stock.